Skip to main content

Newsspecng

​NAFDAC Dismisses Viral Claims of Camosunate Ban in Nigeria

NAFDAC seals Abuja shops for selling unregistered sex enhancers

Releated Post

​The National Agency for Food and Drug Administration and Control (NAFDAC) has refuted widespread social media claims alleging that Camosunate, a widely used antimalarial medication, has been banned in Nigeria.
​In a press statement issued on Saturday and signed by its Director-General, Prof. Mojisola Adeyeye, the regulatory body confirmed that neither Camosunate nor any other medicine containing the artesunate-amodiaquine combination has been prohibited in the country.
​“The Agency clarifies that it has never banned Camosunate or medicines containing the artesunate-amodiaquine combination,” the statement read.
​The clarification follows viral online reports—and a recent dispute in Edo State where a local consumer protection committee sealed a pharmacy over the alleged sale of the drug—claiming the medication had been outlawed due to severe adverse reactions.
​Addressing the health concerns raised in the circulating posts, NAFDAC noted that the symptoms highlighted online align with documented side effects of the medication rather than grounds for a regulatory ban.
​“Some of the symptoms reported in the viral claim may be associated with known side effects of Camosunate, including nausea, vomiting, diarrhoea, abdominal pain, headache, dizziness, drowsiness and loss of appetite,” the agency explained.
​NAFDAC advised Nigerians and healthcare professionals to channel suspected adverse drug reactions through official pharmacovigilance platforms for proper scientific evaluation instead of spreading unverified claims online.
​“Members of the public and healthcare professionals are encouraged to report suspected adverse drug reactions through the NAFDAC Med Safety App, available for download on Android and iOS devices, or at the nearest NAFDAC office,” the statement added.
​Urging the public to halt the spread of misinformation, the agency called on individuals who had already shared the false alert to circulate its official clarification across the same platforms to prevent unnecessary public panic.

Leave a Reply

Your email address will not be published. Required fields are marked *

More Related Posts

Thanks for subscribing to our newsletter